La cadena de opciones muestra datos clave de las opciones de acciones de IGC Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para IGC Pharma..

IGC Pharma (AMEX:IGC) Bolsa, Cadena de Opciones

IGC PHARMA INC

IGC Pharma

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma Inc

TCW Corporate Bond ETF

INTEGRATED CYBR SOLUTIONS by INTEGRATED CYBER SOLUTIONS INC.

Integrated Cyber Solutions Inc

<a href="https://themarijuanaherald.com/2025/06/u-s-congress-house-gop-bill-would-ban-most-hemp-derived-thc-products-nationwide/" title="https://themarijuanaherald.com/2025/06/u-s-congress-house-gop-bill-would-ban-most-hemp-derived-thc-products-nationwide/">https://themarijuanaherald.com/2025/06/u-s-congress-house-gop-bill-would-ban-most-hemp-derived-thc-products-nationwide/</a>

Biotech

News

General

AKAN

CRON

FLGC

GRWG

IMCC

MAPS

MSOS

SNDL

TLRY

'U.S. Congress: House GOP Bill Would Ban Most Hemp-Derived THC Products Nationwide' - Marijuana Herald

<a href="https://www.marijuanamoment.net/california-assembly-unanimously-passes-bill-to-delay-marijuana-tax-hike-for-five-years/" title="https://www.marijuanamoment.net/california-assembly-unanimously-passes-bill-to-delay-marijuana-tax-hike-for-five-years/">https://www.marijuanamoment.net/california-assembly-unanimously-passes-bill-to-delay-marijuana-tax-hike-for-five-years/</a>

'PoliticsCalifornia Assembly Unanimously Passes Bill To Delay Marijuana Tax Hike For Five Years' - Marijuana Moment

<a href="https://www.marijuanamoment.net/trump-wants-to-delete-state-medical-marijuana-protections-from-budget-while-continuing-to-block-cannabis-sales-legalization-in-d-c/" title="https://www.marijuanamoment.net/trump-wants-to-delete-state-medical-marijuana-protections-from-budget-while-continuing-to-block-cannabis-sales-legalization-in-d-c/">https://www.marijuanamoment.net/trump-wants-to-delete-state-medical-marijuana-protections-from-budget-while-continuing-to-block-cannabis-sales-legalization-in-d-c/</a>

Legal

'Trump Wants To Delete State Medical Marijuana Protections From Budget While Continuing To Block Cannabis Sales Legalization In D.C.' - Marijuana Moment

<a href="https://www.marijuanamoment.net/senate-committee-approves-trumps-dea-pick-who-has-refused-to-say-if-he-supports-marijuana-rescheduling-proposal-before-agency/" title="https://www.marijuanamoment.net/senate-committee-approves-trumps-dea-pick-who-has-refused-to-say-if-he-supports-marijuana-rescheduling-proposal-before-agency/">https://www.marijuanamoment.net/senate-committee-approves-trumps-dea-pick-who-has-refused-to-say-if-he-supports-marijuana-rescheduling-proposal-before-agency/</a>

'Senate Committee Approves Trump's DEA Pick Who Has Refused To Say If He Supports Marijuana Rescheduling Proposal Before Agency' - Marijuana Moment

IGC Pharma, Inc. ("IGC", or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer's disease. This strategic site directly addresses the significant impact of Alzheimer's in the region.
Approximately 12.5% of Puerto Ricans over the age of 65 have Alzheimer's, a figure notably higher than the roughly 10% prevalence observed in older non-Hispanic white populations in the U.S. This disparity is influenced by factors such as Puerto Rico's rapidly aging demographic and unique genetic predispositions. The heightened prevalence translates into a substantial economic burden, with medical care for dementia in Puerto Rico accounting for over a quarter of total societal healthcare costs, a proportion higher than in the continental U.S.

IGC Pharma Announce Clinical Trial Site At Santa Cruz Behavioral In Puerto Rico For CALMA Phase 2 Clinical Trial, Investigating IGC-AD1 For Agitation In Alzheimer's Disease

<a href="https://x.com/MarijuanaMoment/status/1925220244504621454" title="https://x.com/MarijuanaMoment/status/1925220244504621454">https://x.com/MarijuanaMoment/status/1925220244504621454</a>

"Marijuana Rescheduling Blocked By Opposition 'From Within' DEA, Biden's Drug Czar Says" - Marijuana Moment

IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay," at the <a href="https://pr.report/ab65">2025 Genetic Toxicology Association Annual Meeting</a>, showcasing key non-clinical data that support the genetic safety profile of one of the two active pharmaceutical ingredients ("API") in IGC-AD1, the Company's investigational drug for Alzheimer's disease.
Part of the FDA's battery of safety requirements is to show that APIs are safe for human consumption, including that they do not alter or mutate genes. IGC completed this requirement and is now able to show that the APIs in IGC-AD1 are safe and do not alter genes.

IGC Pharma Presents Its Latest Scientific Poster, Titled "Genetic Toxicity Evaluation Of Melatonin In The Bacterial Reverse Mutation Assay," At The 2025 Genetic Toxicology Association Annual Meeting

<a href="https://www.marijuanamoment.net/trumps-pick-to-lead-dea-says-marijuana-rescheduling-review-will-be-one-of-my-first-priorities-in-the-job/" title="https://www.marijuanamoment.net/trumps-pick-to-lead-dea-says-marijuana-rescheduling-review-will-be-one-of-my-first-priorities-in-the-job/">https://www.marijuanamoment.net/trumps-pick-to-lead-dea-says-marijuana-rescheduling-review-will-be-one-of-my-first-priorities-in-the-job/</a>

Macro Economic Events

Politics

Economics

LFLY

"Trump's Pick To Lead DEA Says Marijuana Rescheduling Review Will Be 'One Of My First Priorities' In The Job" - Marijuana Moment

<h3>Gainers</h3>
<ul>
<li>Azitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock rose 35.0% to $0.41 during Thursday's after-market session. The company's market cap stands at $6.1 million. </li>
<li>Alector (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALEC#NASDAQ">ALEC</a>) shares moved upwards by 9.11% to $1.28. The company's market cap stands at $126.5 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock rose 8.33% to $0.52. The market value of their outstanding shares is at $72.4 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares rose 7.63% to $1.55. The market value of their outstanding shares is at $6.7 million. </li>
<li>Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) shares rose 6.75% to $318.4. The market value of their outstanding shares is at $12.3 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) shares increased by 6.59% to $0.36. The market value of their outstanding shares is at $25.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares declined by 8.3% to $2.0 during Thursday's after-market session. The market value of their outstanding shares is at $3.4 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) shares decreased by 7.59% to $0.29. The company's market cap stands at $23.1 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares fell 7.04% to $0.22. The company's market cap stands at $1.1 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares declined by 6.52% to $4.59. The market value of their outstanding shares is at $119.3 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 5.96% to $0.98. The market value of their outstanding shares is at $2.8 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) stock declined by 5.92% to $0.46. The market value of their outstanding shares is at $45.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALEC

AZTR

CNSP

MNDR

OVID

PCSA

SNES

SNTI

VNRX

XTNT

12 Health Care Stocks Moving In Thursday's After-Market Session

<a href="https://www.marijuanamoment.net/bipartisan-congressional-lawmakers-file-bill-to-end-federal-marijuana-prohibition-in-legal-states-in-line-with-trumps-stance/" title="https://www.marijuanamoment.net/bipartisan-congressional-lawmakers-file-bill-to-end-federal-marijuana-prohibition-in-legal-states-in-line-with-trumps-stance/">https://www.marijuanamoment.net/bipartisan-congressional-lawmakers-file-bill-to-end-federal-marijuana-prohibition-in-legal-states-in-line-with-trumps-stance/</a>

'Bipartisan Congressional Lawmakers File Bill To End Federal Marijuana Prohibition In Legal States In Line With Trump's Stance' - Marijuana Moment

IGC Pharma Expands Phase 2 CALMA Trial With Site At Butler Hospital's Memory and Aging Program

<a href="https://www.marijuanamoment.net/marijuana-rescheduling-isnt-on-the-white-houses-new-list-of-top-drug-policy-priorities-under-the-trump-administration/" title="https://www.marijuanamoment.net/marijuana-rescheduling-isnt-on-the-white-houses-new-list-of-top-drug-policy-priorities-under-the-trump-administration/">https://www.marijuanamoment.net/marijuana-rescheduling-isnt-on-the-white-houses-new-list-of-top-drug-policy-priorities-under-the-trump-administration/</a>

'Marijuana Rescheduling Isn't On The White House's New List Of Top Drug Policy Priorities Under The Trump Administration' - Marijuana Moment

IGC Pharma Expands CALMA Phase 2 Trial with Miami Jewish Health Addition

IGC Pharma, Inc. ("IGC", or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition of a new clinical site at Hamilton Health Sciences (HHS) in Ontario, Canada. This expansion marks a key milestone in IGC Pharma's strategy to advance IGC-AD1 toward commercialization, accelerating patient enrollment and expanding the Company's clinical footprint.
Hamilton Health Sciences is one of Canada's leading academic and research hospitals. The CALMA trial at HHS will be led by Dr. Alexandra Papaioannou, a distinguished geriatrician and Executive Director of HHS' <a href="https://pr.report/8ht1">Geras Centre for Aging Research</a>, whose expertise in aging, frailty, and dementia will play a critical role in the trial's success.

Global

IGC Pharma Announces CALMA Phase 2 Trial Expansion With The Addition Of Canadian Hamilton Health Sciences In Ontario, Canada

Alliance Global Partners analyst James Molloy reiterates IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) with a Buy and maintains $3.5 price target.

Price Target

Reiteration

Analyst Ratings

Alliance Global Partners Reiterates Buy on IGC Pharma, Maintains $3.5 Price Target

<a href="https://www.marijuanamoment.net/senator-john-fetterman-circulates-petition-to-legalize-marijuana-at-the-federal-level/" title="https://www.marijuanamoment.net/senator-john-fetterman-circulates-petition-to-legalize-marijuana-at-the-federal-level/">https://www.marijuanamoment.net/senator-john-fetterman-circulates-petition-to-legalize-marijuana-at-the-federal-level/</a>

'Senator John Fetterman Circulates Petition To Legalize Marijuana At The Federal Level' - Marijuana Moment

Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) with a Buy and raises the price target from $4 to $4.25.

Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $4.25

<a href="https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/" title="https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/">https://themarijuanaherald.com/2025/02/dea-official-says-marijuana-rescheduling-is-delayed-but-certainly-not-dead/</a>

"DEA Official Says Marijuana Rescheduling Is 'Delayed, But Certainly Not Dead'" - The Marijuana Herald

Management

IGC Pharma Appoints Former VA Governor Terry McAuliffe As A Strategic Advisor

IGC Pharma Names Alzheimer's Agitation Phase 2 Trial "CALMA" And Expands Recruitment With Geofencing Technology, Targeting Completion In 2H 2025 After Achieving 200%-300% Enrollment Boost At Select Sites

Press Releases

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

IGC Pharma Welcomes Strategic Investment from Advisors

Events

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

Contracts

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

AN2 Therapeutics

Aytu BioPharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Gelteq

Grace Therapeutics

Hoth Therapeutics

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Pulmatrix

PolyPid

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Scilex Holding

SCYNEXIS

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies

China SXT Pharmaceuticals, Inc. - Common Stock

Comments

IGC Pharma

IGC Pharma (IGC) Opciones

IGC Pharma (AMEX:IGC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL